WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Earnings & Revenue

RARE past revenue growth

How has RARE's revenue growth performed historically?
Company
15.29%
Industry
89.94%
Market
19.39%
RARE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RARE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RARE's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RARE earnings and revenue history

Current Revenue
$442.6M
Current Earnings
-$613.4M
Current Profit Margin
-138.6%

RARE Return on Equity

Current Company
-425.6%
Current Industry
16.8%
Current Market
28.2%
RARE's Return on Equity (-425.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when RARE announces earnings.

RARE Return on Assets

Current Company
-45.9%
Current Industry
3.2%
RARE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RARE Return on Capital Employed

Current Company
-57.96%
Current Industry
-42.4%
RARE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RARE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RARE$442.59M-$585.60M-$613.35M+49.64%N/A
DYN$0.00-$255.00M-$257.40MN/AN/A
CORT$523.53M$122.89M$117.19M+15.17%+11.75%
ARWR$35.47M-$432.38M-$470.79M-17.85%N/A
IBRX$302.00k-$439.89M-$600.96M+45.07%N/A

RARE earnings dates

Next earnings date
Aug 1, 2024

Ultragenyx Pharmaceutical Earnings & Revenue FAQ

What were RARE's earnings last quarter?

On Invalid Date, Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q1 2024 earnings per share (EPS) of -$2.03, up 12.88% year over year. Total Ultragenyx Pharmaceutical earnings for the quarter were -$170.68 million. In the same quarter last year, Ultragenyx Pharmaceutical's earnings per share (EPS) was -$2.33.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.

What was RARE's earnings growth in the past year?

As of Q3 2024, Ultragenyx Pharmaceutical's earnings has grown year over year. Ultragenyx Pharmaceutical's earnings in the past year totalled -$613.35 million.

What is RARE's earnings date?

Ultragenyx Pharmaceutical's earnings date is Invalid Date. Add RARE to your watchlist to be reminded of RARE's next earnings announcement.

What was RARE's revenue last quarter?

On Invalid Date, Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q1 2024 revenue of $108.83 million up 8.3% year over year. In the same quarter last year, Ultragenyx Pharmaceutical's revenue was $100.50 million.

What was RARE's revenue growth in the past year?

As of Q3 2024, Ultragenyx Pharmaceutical's revenue has grown 15.29% year over year. This is 74.65 percentage points lower than the US Biotechnology industry revenue growth rate of 89.94%. Ultragenyx Pharmaceutical's revenue in the past year totalled $442.59 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.